Guest Author

Shareholder Representative Services’ latest Q&A features Amr Salahieh.  Salahieh is the founder of Shifamed LLC, a Silicon Valley-based medical device incubator founded in 2009. Shifamed recently sold Maya Medical, a medical device company focused on the treatment of hypertension, to Covidien in a deal valued at up to $230 million. Salahieh discusses the incubator model, […]

Shareholder Representative Services’ latest Q&A features Troy Wilson.  Wilson led Intellikine to an acquisition by Millennium, a U.S. subsidiary of Takeda, for up to $310 million. As a serial entrepreneur, he looks for opportunities with clear value inflection points that bring discipline to the development process. He discusses his approach to value creation, the difference […]

Just three months after taking the helm as CEO, Rodio led Redbeacon, an online platform that allows consumers to interact with local businesses and professionals, to an acquisition by The Home Depot.

Life sciences & biotech investors will want to heed the advice guest poster SRS "Achieving the Exit" Q&A subject Michael Gilman offers.

Shareholder Representative Services’ latest Q&A features Steve Papa.  Papa led Endeca, the Cambridge, Mass.-based provider of unstructured data management, web commerce and business intelligence software, to an acquisition by Oracle in December 2011. He emphasizes the “relentless pursuit of credibility” to best position a startup for hiring, customer acquisition, and ultimately, achieving the exit. Q: What […]

Despite the fact that often times the majority rules, that doesn’t mean the majority is right. The most poignant example comes from a premier venture capital firm I once worked for. One of the opportunities they gave their investment professionals was the opportunity to invest personally and on a discretionary basis in each round of […]

In 1998 I was asked to speak at Mac World. It marked the first time Steve Jobs had returned to his company and would speak at the famous Mac World event. What I didn't know when invited was that I was scheduled to speak immediately after Mr. Jobs. I, like everyone else in the audience, sat mesmerized as he stepped comfortably back into his old shoes and articulated a simple plan for reforming Apple Computer. Things were so bad at the company at that moment Michael Dell famously quipped 'Steve should shut down the company and give the money back to stock holders.' Michael later regretted the statement when Apple’s market value sky rocketed past his own company’s. Nobody really believed Apple could be saved, and even though I was speaking at Mac World I was not so sure myself.

Steve Jobs is gone. The media will be talking for days and weeks about the premature loss of a one-of-a-kind genius, one who had a magic-like insight into what people wanted even before they themselves knew it, to spur passion into dull pieces of electronics, to redefine fashion and style. For us here at Battery […]

“Don’t you know that you are a shooting star, And all the world will love you just as long, As long as you are.” – Paul Rodgers, Shooting Star With the IPO market now blown wide-open, and the media completely infatuated with frothy trades in the bubbly late stage private market, it is common to see articles that reference both “valuation” and “revenue” and suggest that there is a correlation between the two. Calculating or qualifying potential valuation using the simplistic and crude tool of a revenue multiple (also known as the price/revenue or price/sales ratio) was quite trendy back during the Internet bubble of the late 1990s. Perhaps it is not peculiar that our good friend the price/revenue ratio is back in vogue. But investors and analysts beware; this is a remarkably dangerous technique, because all revenues